The current phase 2 clinical trial (NCT05393466) aims to evaluate the safety, tolerability, pharmacokinetics, and anti-tumour activity of BPI-361175 in advanced NSCLC patients with EGFRC797S mutation and other EGFR related mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.